LEYNYSO

Serial Number 99155751
641

Registration Progress

Application Filed
Apr 25, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Non-Final Action Mailed
Due: Dec 17, 2025 45 days

Trademark Image

LEYNYSO

Basic Information

Serial Number
99155751
Filing Date
April 25, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
641
Status Date
Sep 17, 2025
Application
Pending
Classes
005 044

Rights Holder

USWM CT, LLC

16
Address
4441 SPRINGDALE ROAD
LOUISVILLE, KY 40241

Ownership History

Adaptimmune Limited

Original Applicant
16
Oxford GB

USWM CT, LLC

New Owner Before Publication #1
16
LOUISVILLE, KY

Legal Representation

Attorney
Christiane S. Campbell

USPTO Deadlines

Next Deadline
45 days remaining
Non-Final Action Mailed
Due Date
December 17, 2025
Extension Available
Until March 17, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

10 events
Date Code Type Description Documents
Sep 17, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 17, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 17, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 17, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 3, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 3, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Apr 30, 2025 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Apr 30, 2025 TAEA I TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED Loading...
Apr 25, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Apr 25, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Cell therapy pharmaceutical preparations; immunotherapy preparations; T-cell receptors; immunotherapy preparations comprising engineered T-cell receptors; immunotherapy preparations comprising genes encoding engineered T-cell receptors
Class 044
Cell therapy medical treatment services; immunotherapy services; medical treatment and immune-therapy comprising harvesting a patient’s white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient

Classification

International Classes
005 044